Stay updated on Selinexor Maintenance in p53 Wild-Type Endometrial Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Selinexor Maintenance in p53 Wild-Type Endometrial Carcinoma Clinical Trial page.

Latest updates to the Selinexor Maintenance in p53 Wild-Type Endometrial Carcinoma Clinical Trial page
- Check8 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2. This reflects a routine version update in the site's revision history.SummaryDifference0.0%

- Check16 days agoChange DetectedThe study page now shows 217 locations, and multiple investigator contacts and site entries (e.g., Istanbul, Ankara, and Seoul St. Mary’s Hospital) have been removed, changing the total location count.SummaryDifference0.3%

- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedGlossary toggle added; page metadata updated to include Last Update Submitted that Met QC Criteria and Last Update Posted. The revision is updated to v3.4.0 and older No FEAR Act data entries were removed.SummaryDifference0.0%

- Check38 days agoChange Detected- Revision: v3.3.4 is now displayed, replacing Revision: v3.3.3. This is a minor metadata update that does not alter the study content or how users interact with the page.SummaryDifference0.0%

- Check59 days agoChange DetectedRecruitment status updated to Recruiting with new contacts added: Rebecca Brooks; Principal Investigator Joan Tymon-Rosario; and investigators Prafull Ghatage and Wei-Yu Chen (cwycwy600222@gmail.com). Removed Not yet Recruiting listings for Steven Bisch and Yin-Hsun Feng (yinhsun.feng@gmail.com).SummaryDifference0.3%

- Check66 days agoChange DetectedThe Study Details page now lists a broad set of recruitment sites across the US, Canada, Australia, and Europe (e.g., Alabama, Athens, Elm Park, Gipuzkoa, Ankara), replacing the previous locations list.SummaryDifference0.8%

Stay in the know with updates to Selinexor Maintenance in p53 Wild-Type Endometrial Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Selinexor Maintenance in p53 Wild-Type Endometrial Carcinoma Clinical Trial page.